StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) stock

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$143.37−1.09 (-0.75%)

Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%

Merck revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Merck's revenue for the twelve months ending Jun 30, 2026 was $66.57B, up 4.6% year over year. For fiscal 2025 it was $65.01B, up 1.3% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $65.01B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$65.01B+1.3%
FY2024Dec 31, 2024$64.17B+6.7%
FY2023Dec 31, 2023$60.12B+1.4%
FY2022Dec 31, 2022$59.28B+21.7%
FY2021Dec 31, 2021$48.70B+17.3%
FY2020Dec 31, 2020$41.52B+6.1%
FY2019Dec 31, 2019$39.12B-7.5%
FY2018Dec 31, 2018$42.29B+5.4%
FY2017Dec 31, 2017$40.12B+0.8%
FY2016Dec 31, 2016$39.81B+0.8%
FY2015Dec 31, 2015$39.50B-6.5%
FY2014Dec 31, 2014$42.24B-4.1%
FY2013Dec 31, 2013$44.03B-6.8%
FY2012Dec 31, 2012$47.27B-1.6%
FY2011Dec 31, 2011$48.05B+4.5%
FY2010Dec 31, 2010$45.99B+67.7%
FY2009Dec 31, 2009$27.43B+15.0%
FY2008Dec 31, 2008$23.85B-1.4%
FY2007Dec 31, 2007$24.20B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.61B+5.1%
Q1 FY2026Mar 31, 2026$16.29B+4.9%
Q4 FY2025Dec 31, 2025$16.40B+5.0%
Q3 FY2025Sep 30, 2025$17.28B+3.7%
Q2 FY2025Jun 30, 2025$15.81B-1.9%
Q1 FY2025Mar 31, 2025$15.53B-1.6%
Q4 FY2024Dec 31, 2024$15.62B+6.8%
Q3 FY2024Sep 30, 2024$16.66B+4.4%
Q2 FY2024Jun 30, 2024$16.11B+7.2%
Q1 FY2024Mar 31, 2024$15.78B+8.9%
Q4 FY2023Dec 31, 2023$14.63B+5.8%
Q3 FY2023Sep 30, 2023$15.96B+6.7%
Q2 FY2023Jun 30, 2023$15.04B+3.0%
Q1 FY2023Mar 31, 2023$14.49B-8.9%
Q4 FY2022Dec 31, 2022$13.83B+2.3%
Q3 FY2022Sep 30, 2022$14.96B+13.7%
Q2 FY2022Jun 30, 2022$14.59B+28.0%
Q1 FY2022Mar 31, 2022$15.90B+49.6%
Q4 FY2021Dec 31, 2021$13.52B+23.5%
Q3 FY2021Sep 30, 2021$13.15B+20.4%
Q2 FY2021Jun 30, 2021$11.40B+21.9%
Q1 FY2021Mar 31, 2021$10.63B-11.9%
Q4 FY2020Dec 31, 2020$10.95B+163.9%
Q3 FY2020Sep 30, 2020$10.93B-11.8%
Q2 FY2020Jun 30, 2020$9.35B-20.5%
Q1 FY2020Mar 31, 2020$12.06B+11.5%
Q4 FY2019Dec 31, 2019$4.15B-62.3%
Q3 FY2019Sep 30, 2019$12.40B+14.9%
Q2 FY2019Jun 30, 2019$11.76B+12.4%
Q1 FY2019Mar 31, 2019$10.82B+7.8%
Q4 FY2018Dec 31, 2018$11.00B+5.4%
Q3 FY2018Sep 30, 2018$10.79B+4.5%
Q2 FY2018Jun 30, 2018$10.47B+5.4%
Q1 FY2018Mar 31, 2018$10.04B+6.4%
Q4 FY2017Dec 31, 2017$10.43B+3.1%
Q3 FY2017Sep 30, 2017$10.33B-2.0%
Q2 FY2017Jun 30, 2017$9.93B–
Q1 FY2017Mar 31, 2017$9.43B–
Q4 FY2016Dec 31, 2016$10.12B–
Q3 FY2016Sep 30, 2016$10.54B–

More Merck figures

See a number that looks wrong?